

Greater Manchester Medicines Management Group

Minutes of the meeting held on
Thursday 10th June 2021, 1- 3pm

Virtual meeting

Present:

Name	Title	Organisation	Representing	Jul	Aug	Sep	Oct	Nov 20	May 21	Jun
Dr Helen Burgess (HB)	GP MO Prescribing lead	NHS Manchester CCGs	GPs	✓	A	✓	✓	✓	✓	✓
Dr Pete Budden (PB)	GP Prescribing lead	Salford CCG	MGSG		A	A				
Petra Brown (PeB)	Chief Pharmacist	Pennine care NHS FT	GM Mental Health Organisations	✓ (JW)	✓ (JW)	✓ (JW)	✓	✓	✓	✓
Dr Richard Darling (RD)	GP Prescribing Lead	Heywood, Middleton and Rochdale CCG	PaGDSG		A	A			✓	
Kate Rigden (KR)	Deputy Chief Finance Officer	NHS Oldham CCG	CCG finance leads	✓	A	✓	✓	✓	✓	A
Ruth Dales (RuD)	Lead Pharmacist	GM AHSN	Health Innovation Manchester (HIM)	✓	✓	✓	✓	✓	A	✓

Dr Ann Harrison (AH)	GP MO Prescribing lead	Trafford CCG	GPs	A	✓	✓	✓	✓	✓	✓
Robert Hallworth (RH)	Specialist Cancer Pharmacist	NHSE	NHSE Specialised Commissioning	✓	A	A	✓	✓	✓	✓
Peter Howarth (PH)	Head of Medicines Management	Tameside & Glossop CCG	CCG MO leads	✓	✓	✓	✓	✓	✓	✓
Dr Daljit Saroya	Consultant Anaesthetist and Chair of MO committee at Stockport FT	Stockport FT	GM Secondary Care Clinicians	✓	A	✓	✓			
Leigh Lord (LL)	Locality Lead Pharmacist	NHS Trafford CCG	CCG MO leads	✓	✓ (KL)	✓	✓	✓	✓	✓ CH
Peter Marks (PM)	LPC Board Member	GM LPC	Community Pharmacy	✓	✓	✓	✓	✓	A (LK as below)	✓
Fiona Meadowcroft (FC)	Interim Deputy Director Strategy – Integrated Care	MHCC	CCG Commissioning lead		✓	✓	✓	✓	✓	✓
Karen O’Brien (KO’B)	Regional Pharmacist	NHSEI	NHSEI	✓	✓	✓	✓	✓	✓	✓
Dr Jeff Schryer	JCB clinical lead for MO	The GM Joint Commissioning Board (MO)	JCB	✓	A	A	A	A	A	A
Steve Simpson (SS) Or Paul Buckley (PaB)	Chief Pharmacist	Bolton FT Stockport FT	GM Chief pharmacists	✓	A	✓ (PaB)	✓	✓	✓ (PaB)	✓
Charlotte Skitterall (CS)	Chief Pharmacist	Manchester FT	Chair	✓	✓	A	✓	✓	✓	✓
Claire Vaughan (CV)	Head of MO	Salford CCG	Vice Chair	✓	A	✓	✓	✓	✓	✓

Dr Sanjay Wahie (SW)	Clinical Director	NHS Wigan CCG	GPs	✓	A	✓	✓	A	✓	✓
Dr Peter Elton	SCN representatives	Strategic Clinical Network	Strategic Clinical Network	✓	✓	✓	✓	✓	✓	✓
Vacant seat			Provider Board representative							
Vacant seat			Council representative for GM Social Services							
Vacant seat			GM Medical Directors							
Vacant seat			Lay representative							
Vacant seat			GM Public Health							
Sue Dickinson (SD)	Director of Pharmacy	RDTC	SPS	✓	✓	✓	✓	✓	✓	✓
Monica Mason (MM)	Head of Prescribing Support	RDTC	Professional secretary	✓	✓	✓	✓	✓	✓	✓
Andrew Martin (AM)	MO Pharmacist	GM Joint Commissioning team	GMMM support	✓ AM	✓ AM	✓ AM	✓	✓	✓	✓
Andrew White (AW)	Head of MO	GM Joint Commissioning team	GMMM support	✓	✓	✓	✓	✓	✓	✓
Dan Newsome (DN)	Principal pharmacist	RDTC	GMMM support	A	✓	✓	✓	✓	A	A

1. General Business

1.1 Apologies

As above, Chris Haig attended in LL place.

1.2 Declarations of Interest

Nil declared

2.0 Minutes and actions from the last meeting

The minutes of the May meeting were approved for publication; the group were updated on the progress of outstanding actions as recorded in the action log

3.0 Integrating Pharmacy and Medicines Optimisation – update

The group discussed in detail the ask of this programme, and how it would be delivered within the current GMMMG resource, against what was already on the agreed GMMMG work plan. The steps limiting progress were discussed, in particular changes in the governance structure within the HSCP and the impact this has on GMMMG as a medicines board going forward.

There was significant discussion on the need for a GM Value programme, and that this was not simply about savings. A further value work stream/group was discussed. It was agreed that all four current work stream groups would return plans for their two priority pieces through the group lead in time for July GMMMG. It was also agreed that two priority value pieces should be submitted, so that GMMMG can agree whether a separate Value group is needed or if these pieces can be incorporated into the other work streams.

It was agreed that system wide pharmacy representation was essential to the delivery of the IPMO plan, and that the successes of an integrated medicines and pharmacy approach as delivered by GMMMG should be strengthened, both to deliver the IPMO programme but also to ensure an effective medicines board for the ICS.

Post-meeting note: the July GMMMG meeting was agreed to run as an IPMO workshop

Action: Workstream leads to return two priorities per work stream to the next GMMMG, in addition CCG leads to submit Value priorities. AW/MM to coordinate these priorities into the current work plan and assign resource requirements.

4.0 GMMMG Work Plan performance monitor

JCT updated the group on progress made utilising the Tableau platform to prepare a GM medicines dashboard, building on that already available from the HSCP, and that it was hoped the test site would be ready to present at the July/August meetings. It was accepted that changes to the current work plan resulting from the above IPMO discussions would need to be incorporated in due course.

It was also recognised that there are other data and reporting facilities available to the GM system which are currently being developed e.g. Model Hospital, Model Health, RDTc Population Health reports and that these should also be utilised, and that all efforts should be taken to avoid duplication of effort or reinvention of available resources.

Action: JCT/RDTc/KO'B to collaborate to understand the data that will be available from the different national and regional platforms and how these could be best utilised to monitor the agreed IPMO/GMMMG priorities (once agreed). To return a demo performance dashboard to GMMMG.

5.0 Commissioning of shared care across GM – progress report

The group were given a verbal update on the progress of this work stream but requested a written report return to the next meeting. It was agreed that the Azathioprine SCP be submitted to DoCs as per the new format which will indicate the commissioning position of each CCG, pending the move to a single GM commissioning position.

Action: AW to submit AZA SCP to DoCs ASAP. The group requested a written update around the progress made on GM SC commissioning discussions for the July GMMMG meeting.

6.0 Aducanumab for mild cognitive impairment and mild dementia caused by Alzheimer's disease – managed entry into GM system

The points raised through MGSG were considered, alongside the ask that GMMMG initiate discussions begin at an ICS-level around the service implications should NICE publish a positive TA for this agent. MGSG recommended that the introduction of this drug is looked at as a system-wide pathway due to the complex issues associated with diagnosis, assessment of eligibility and treatment. GMMMG agreed that PB or RH attend DoCs to communicate the potential impact in order that GM wide discussions can begin early. PB also agreed to contact Sandy Bering, and to return an update to GMMMG. MGSG are asked to raise concerns to NICE at this stage around monthly PET scans etc.

Action: as detailed above

7.0 NICE NG196: AF: Diagnosis and prevention –finance and commissioning impact

GMMMG considered a commissioning impact report submitted on behalf of MGSG detailing the recent NICE recommendations for the clinical management of atrial fibrillation. These are likely to have a significant financial impact and the potential for changes in the way anticoagulation monitoring services are commissioned across GM.
GMMMG asked that this decision

Action: As detailed above.

8.0 CQC report – Healthcare at home

This report was noted by the group, it is understood that corrective actions have been undertaken.

Action: No further action required

9.0 Communication from Subgroups and Associated Committees

NHSE – updated on IPMO discussions

RMOC - The group were reminded that there are consultations running regarding the revised RMOC terms of reference and the first set of draft RMOC national shared care protocols.

GM CCG MO leads – updated on IPMO discussions

GM Chief Pharmacists – updated on pharmacy central stores work

Health Innovation Manchester (AHSN) – will submit HiM updates when papers ready to the next GMMMG

IPMC – updated on inclisiran trial, information to be shared with membership by email

10. AOB

Date of next virtual meeting: Thursday 8th July 2021, 1 – 3pm